shcri.com - Autism Spectrum Disorders (ASD) is a group of incurable, developmental disabilities which affect the brain and are usually diagnosed between the ages of 18-24 months. ASD encompasses a broad spectrum of disorders in which the severity of the condition, the nature of impairment, the social and communication skills, time of onset of the condition, and the way the brain perceives information, vary among the affected individuals (ADDM, 2012; CDC, 2012a; NIHM, 2007). Epidemiological literature suggests an increase in the diagnosed prevalence of ASD over time. However, it remains unclear whether the increase in the diagnosed prevalence is due to a true increase in the prevalence of ASD, or due to an increase in the diagnosis of ASD because of an increased availability and utilization of health services (Williams et al., 2006).
EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022 provides an overview of the risk factors, comorbidities and global trends for ASD in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022 provides a 10-year epidemiological forecast (2012-2022) of the diagnosed prevalent cases of ASD as per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or the International Classification of Diseases, 10th Revision (ICD-10) diagnostic criteria, segmented by sex and age (in five-year increments, beginning at age 0 years and ending at 19 years) for the 6MM. The epidemiologists also provide a forecast of the diagnosed prevalent cases of the different subtypes of ASD, among ASD patients for the 5EU markets (France, Germany, Italy, Spain, and UK). EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022 utilized nationally representative data from peer-reviewed journals and governmental documents to provide the age- and sex-specific prevalence of diagnosed ASD in the respective markets. The forecast methodology was consistent across all of the 6MM to allow for a meaningful comparison among them.
In 2012, there were 1,826,542 diagnosed prevalent cases of ASD in the 6MM, with approximately 90% of the diagnosed prevalent cases (1,630,499) in the US alone. EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022 forecasts that there will be 1,952,647 diagnosed prevalent cases of ASD in the 6MM by 2022, with an overall average annual growth rate (NYSE:AGR) of 0.69% during the forecast period.
To summarize, EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022 projects an increase in the diagnosed prevalent cases of ASD in all of the 6MM except for Germany and Italy, where it is expected to remain relatively stable. The epidemiologists attribute this mainly to the changing population demographics in the 6MM."